Hidradenitis Suppurativa Clinical Trials

Home | Studies | Hidradenitis Suppurativa Clinical Trials

Are Those Painful Bumps Bothering You?

Hidradenitis Suppurativa Clinical Trials May Be The Right Choice For You!

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition caused by the occlusion of hair follicles. Recent research has found that the overall prevalence of hidradenitis suppurativa is around 0.40%, which means about 1 in 250 people have this condition.

If you or someone you know have Hidradenitis Suppurativa, Revival Research Institute is conducting Hidradenitis Suppurativa Clinical Trials, exploring potential new treatment options.

To participate in the Hidradenitis Suppurativa Clinical Trials, you must:

Be above the age of 18 years
Have been diagnosed with moderate to severe HS
Have HS lesions in at least two different areas on your body

*Additional Criteria may apply

Even though HS is a fairly common condition, there is little research on it. Revival Research Institute is conducting a clinical trial investigating a potential Hidradenitis Suppurativa treatment option.

**Participation in the Hidradenitis Suppurativa Clinical Trials is free of cost. To learn more or to enroll, fill out the form and someone from the research team will contact you to discuss if you may be eligible to participate in the study.

*Who is this information for?

A Family Member

A Friend

My Patient

Please provide YOUR contact information only.

First Name

Last Name

Phone

Confirm Phone

Best time to call?

Morning

Middle of the day

Evening

State

How did you hear about us?*

Comments

User Agreement*

By Signing up, I agree to be contacted via calls and SMS.

About the Hidradenitis Suppurativa Clinical Trials

We’re conducting a phase III clinical trial for Hidradenitis Suppurativa. The goal of the study is to test out the safety and efficacy of a Hidradenitis Suppurativa treatment (investigational) that may help reduce moderate to severe symptoms.

The study is investigating a potential Hidradenitis Suppurativa treatment option that acts as a potent inhibitor of interleukin 17-A and may reduce the severity of Hidradenitis Suppurativa and other diseases associated with interleukin 17-A. The medication is to be taken in the form of a subcutaneous injection once every week. Since this is a placebo-controlled clinical trial — participants may either receive the placebo (a drug with no active ingredient) or the study drug.

If you are eligible for the study and decide to participate, you may be asked by the study team to attend scheduled visits which may include physical examinations, blood draws, and questionnaires. A dedicated research team, including doctors and nurses, will monitor your health throughout the study. Participation in the Hidradenitis Suppurativa clinical trials is completely voluntary.

*No insurance is required to participate. Participants will receive study-related care completely free of cost.
*To participate, fill out the form above, and one of our research staff will contact you to see if you may be eligible for the study. They may ask you a few questions related to your health and medical history to see if you may be eligible.

Get Started: What to Expect?

Participation in the study may last up to 63 weeks. If you are eligible and decide to participate, you will be given either the study drug or a placebo which you will have to take every week through a subcutaneous injection. Neither you nor the study doctor will know which medication you receive. The study team will provide complete information to you regarding the Hidradenitis Suppurativa clinical trials and the study medication before you decide to participate during the Informed Consent process.

There may be multiple clinic visits for the study. The study team will discuss all the details of the study’s visits during the Informed Consent process. Participation in the Hidradenitis Suppurativa clinical trials is completely voluntary. Insurance is not required to participate. And all participants may receive compensation for their time and travel during the study.

Throughout the study, while you are taking the medication, your health will be monitored by a qualified research team, including doctors and nurses. We encourage all participants to ask as many questions as they’d like before deciding to participate in any research study.

Age:

18 years or older

Condition:

Hidradenitis Suppurativa

Location:

Michigan

Hidradenitis Suppurativa: The Painful Confidence Crusher

hidradenitis suppurativa clinical trials is enrolling

People with Hidradenitis Suppurativa develop painful inflamed nodules, abscesses, pus-discharging tracts, and fistula, which typically occur in areas where skin comes into contact with skin like:

Armpits (axillary region)
Groin (inguinal region)
Gluteal and perineal areas of the body

Hidradenitis Suppurativa can act like a confidence crusher for many people. The severe pain, movement restriction, and foul-smelling pus discharge can have a negative impact on one’s life.

A variety of etiological factors are known to cause it. Genetics, smoking, being overweight, and hormonal factors are responsible. Clinical management of Hidradenitis Suppurativa symptoms is challenging, and it comprises both medical and surgical approaches. Currently, there are topical therapies, systemic antibiotics, hormonal therapies, and immunosuppressant medications. However, there are instances where it remains resistant to conventional treatments and investigating novel treatment options for dermatology conditions becomes imperative.

Frequently Asked Questions

What is Hidradenitis Suppurativa?

It is a chronic inflammatory condition causing pus-filled inflammatory nodules in the armpits, groin, gluteal and perineal region. Hidradenitis Suppurativa symptoms can be extremely painful and negatively affect an individual’s mental and physical well-being.

What causes Hidradenitis Suppurativa symptoms?

The symptoms of Hidradenitis Suppurativa can be caused by a combination of factors. Some of the main contributors include genetic predisposition, lifestyle choices such as smoking, being overweight, hormonal imbalances, and other potential triggers.

How to get rid of Hidradenitis Suppurativa?

Getting rid of Hidradenitis Suppurativa completely can be challenging, but several approaches can help manage the condition and alleviate symptoms. Here are some strategies commonly used:

Medical treatments: Consult with a dermatologist or healthcare professional who can prescribe medications to manage symptoms. Antibiotics, anti-inflammatory drugs, and hormonal therapies are commonly prescribed.

Proper hygiene: Maintain good personal hygiene by keeping the affected areas clean and dry. Gentle cleansing with mild soap and warm water is recommended.

Warm compresses: Applying warm compresses to the affected areas can help reduce pain and promote drainage of abscesses or nodules.

Weight management: If excess weight is a contributing factor, maintaining a healthy weight through proper diet and regular exercise may help improve symptoms.

Smoking cessation: Quitting smoking can significantly improve the symptoms and progression of Hidradenitis Suppurativa.

Dressing and wound care: Properly dressing and caring for open wounds or lesions can help prevent infection and promote healing.

Lifestyle modifications: Avoid tight clothing that can irritate the affected areas and increase friction. Choose breathable fabrics and loose-fitting clothing instead.

Stress management: High levels of stress can potentially worsen symptoms. Implement stress-reduction techniques such as exercise, meditation, or therapy.

It’s important to note that the effectiveness of these strategies can vary from person to person. It’s best to work closely with a healthcare professional to develop a personalized treatment plan based on your specific situation.

How long will the study last?

The Hidradenitis Suppurativa clinical trials may last up to 63 weeks. The study team will provide you with details of the study, including the duration of the study and the number of visits that may occur.

How will the study drug be administered?

The study drug will be administered subcutaneously through injection once every week. The study staff will provide eligible participants with further details.